SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
October 11, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations
September 29, 2022 08:15 ET
|
SELLAS Life Sciences Group, Inc.
GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect -GFH009 at pH 6.0 Decreased Potential for Infusion Reaction and Made Dosing Better Tolerated After Multiple Doses or...
SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting
September 22, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...
SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th
September 14, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...
SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022
September 08, 2022 08:00 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
August 24, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
- Neuroendocrine Prostate Cancer is Growing Unmet Medical Need - NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of Directors
August 16, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results
August 11, 2022 16:12 ET
|
SELLAS Life Sciences Group, Inc.
– Reported Encouraging Updated Data in Q2 from Two Clinical Trials of Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors– – Provides Clinical Update for GFH009 Program – – Cash Position...
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
August 09, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines - - In Three of the Four Cell Lines, GFH009 Inhibited Cancer Growth by 90 to 100 Percent - NEW YORK, Aug. 09, 2022 ...
SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009
July 07, 2022 07:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...